Samsung Bioepis names Kyung-Ah Kim President and Chief Executive Officer of the company

(Image credit: AdobeStock/peshkova)

Samsung Bioepis has named Kyung-Ah Kim President and Chief Executive Officer of the company. Kim will succeed Christopher Hansung Ko, who has been appointed to lead Samsung Future Business Division.¹

As a veteran scientist with more than 20 years of experience in biologic development, Kim served the Samsung Bioepis as Development Division Leader since December 2021, overseeing all of company’s product development cycle across various therapeutic areas. She joined the company in 2015 and has held various leadership posts within Development Division. Prior to joining Samsung Bioepis, Kim worked as Principal Scientist and later as Vice President at Samsung Advanced Institute of Technology (SAIT) leading Biotherapeutics Group focusing on development of antibody therapeutics targeting oncology.¹

Before joining SAIT, she worked as a scientist/head of cell biology at multiple biopharmaceutical companies, leading various projects on development of therapeutic agents, including genetic sequencing and profiling, development of drug screening assays, pre-clinical assessment, pharmacological assessment, and functional assessment of antibodies.¹

Kim holds a Ph.D in neurotoxicology from The Johns Hopkins University where she established signal transduction pathway, specifically in the learning impairment caused by genetic perturbation in lead poisoning.¹

Samsung Bioepis in biosimilars

Notably, Samsung Bioepis is a key player in the biosimilar realm. The company’s biosimilar, SB15, which is now known by the brand name OPUVIZ, a 40 mg/mL solution for injection in a vial, was approved by the European Commission (EC) for use in adult patients for the treatment of neovascular (wet) age related macular degeneration (AMD), visual impairment due to macular edema secondary to retinal vein occlusion (RVO; branch or central RVO), visual impairment due to diabetic macular edema (DME), and visual impairment due to myopic choroidal neovascularization (myopic CNV) in November of 2024.²

Reference:

1. Kyung-Ah Kim Named as President and Chief Executive Officer of Samsung Bioepis. Samsung Bioepis Co., Ltd. November 27, 2024. Accessed December 6, 2024. https://www.globenewswire.com/news-release/2024/11/27/2987950/0/en/Kyung-Ah-Kim-Named-as-President-and-Chief-Executive-Officer-of-Samsung-Bioepis.html

2. Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™. Samsung Bioepis Co., Ltd. November 18, 2024. Accessed November 18, 2024. https://www.samsungbioepis.com/en/newsroom/newsroomView.do?idx=424&currentPage=1